Valuation dashboard for Black Diamond Therapeutics, Inc. (BDTX) with P/E N/A, P/B 1.15, EV/EBITDA -2.92 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor.
Valuation Ratios
| Price / Book | 1.15 |
| EV / EBITDA | -2.92 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | $111M | 1.15 | -38.8% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.94 |
| Market Cap | $111M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -38.80% |
| Return on Invested Capital | -45.91% |
| Return on Assets | -34.04% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AARD · ABEO · AVTX · CRBU · ENTA · FENC · FHTX
Explore sector: Healthcare · Biotechnology
More sections of BDTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks